|
1
|
Wilhelm SM, Dumas J, Adnane L, Lynch M,
Carter CA, Schütz G, Thierauch KH and Zopf D: Regorafenib (BAY
73-4506): A new oral multikinase inhibitor of angiogenic, stromal
and oncogenic receptor tyrosine kinases with potent preclinical
antitumor activity. Int J Cancer. 129:245–255. 2011.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Krishnamoorthy SK, Relias V, Sebastian S,
Jayaraman V and Saif MW: Management of regorafenib-related
toxicities: A review. Therap Adv Gastroenterol. 8:285–297.
2015.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Grothey A, Van Cutsem E, Sobrero A, Siena
S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, et
al: Regorafenib monotherapy for previously treated metastatic
colorectal cancer (CORRECT): An international, multicentre,
randomised, placebo-controlled, phase 3 trial. Lancet. 381:303–312.
2013.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Li J, Qin S, Xu R, Yau TC, Ma B, Pan H, Xu
J, Bai Y, Chi Y, Wang L, et al: Regorafenib plus best supportive
care versus placebo plus best supportive care in Asian patients
with previously treated metastatic colorectal cancer (CONCUR): A
randomised, double-blind, placebo-controlled, phase 3 trial. Lancet
Oncol. 16:619–629. 2015.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Zhao B and Zhao H: Incidence and risk of
hematologic toxicities in cancer patients treated with regorafenib.
Oncotarget. 8:93813–93824. 2017.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Gerber HP, Malik AK, Solar GP, Sherman D,
Liang XH, Meng G, Hong K, Marsters JC and Ferrara N: VEGF regulates
haematopoietic stem cell survival by an internal autocrine loop
mechanism. Nature. 417:954–958. 2002.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Hattori K, Heissig B, Wu Y, Dias S, Tejada
R, Ferris B, Hicklin DJ, Zhu Z, Bohlen P, Witte L, et al: Placental
growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+)
stem cells from bone-marrow microenvironment. Nat Med. 8:841–849.
2002.PubMed/NCBI View
Article : Google Scholar
|
|
8
|
George JN and Aster RH: Drug-induced
thrombocytopenia: Pathogenesis, evaluation, and management.
Hematology Am Soc Hematol Educ Program 153-158, 2009.
|
|
9
|
Salib M, Clayden R, Clare R, Wang G,
Warkentin TE, Crowther MA, Lim W, Nazi I, Kelton JG and Arnold DM:
Difficulties in establishing the diagnosis of immune
thrombocytopenia: An agreement study. Am J Hematol. 91:E327–E329.
2016.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Kelton JG, Vrbensky JR and Arnold DM: How
do we diagnose immune thrombocytopenia in 2018? Hematology Am Soc
Hematol Educ Program. 2018:561–567. 2018.PubMed/NCBI View Article : Google Scholar
|
|
11
|
McMillan R, Wang L, Tomer A, Nichol J and
Pistillo J: Suppression of in vitro megakaryocyte production by
antiplatelet autoantibodies from adult patients with chronic ITP.
Blood. 103:1364–1369. 2004.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Zhang D, Li H, Ma L, Zhang X, Xue F, Zhou
Z, Chi Y, Liu X, Huang Y, Yang Y and Yang R: The defective bone
marrow-derived mesenchymal stem cells in patients with chronic
immune thrombocytopenia. Autoimmunity. 47:519–529. 2014.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Zhang JM, Feng FE, Wang QM, Zhu XL, Fu HX,
Xu LP, Liu KY, Huang XJ and Zhang XH: Platelet-derived growth
factor-BB protects mesenchymal stem cells (MSCs) derived from
immune thrombocytopenia patients against apoptosis and senescence
and maintains MSC-mediated immunosuppression. Stem Cells Transl
Med. 5:1631–1643. 2016.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Radwi M and Cserti-Gazdewich C:
Drug-induced immune thrombocytopenia associated with use of
tyrosine kinase inhibitor imatinib. J Taibah University Med Sci.
10:365–368. 2015.
|
|
15
|
Ansari Z and George MK: Drug-induced
immune-mediated thrombocytopenia secondary to sunitinib in a
patient with metastatic renal cell carcinoma: A case report. J Med
Case Rep. 7(54)2013.PubMed/NCBI View Article : Google Scholar
|
